Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine.

Hilberink, J.R.; van Zeventer, I.A.; Chitu, D.A.; Pabst, T.; Klein, S.K.; Stussi, G.; Griskevicius, L.; Valk, PJM; Cloos, J.; van de Loosdrecht, A.A.; Breems, D.; van Lammeren-Venema, D.; Boersma, R.; Jongen-Lavrencic, M.; Fehr, M.; Hoogendoorn, M.; Manz, M.G.; Söhne, M.; van Marwijk Kooy, R.; Deeren, D.; van der Poel, MWM; Legdeur, M.C.; Tick, L.; Chalandon, Y.; Ammatuna, E.; Blum, S.; Löwenberg, B.; Ossenkoppele, G.J.; Huls, G.

doi:10.1038/s41408-023-00850-6

Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine.

Details

Download: 37336890_BIB_4F3DD7E2D528.pdf (2082.41 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0

Serval ID

serval:BIB_4F3DD7E2D528

Type

Article: article from journal or magazin.

Collection

Publications

Institution

UNIL/CHUV

Title

Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine.

Journal

Blood cancer journal

Author(s)

Hilberink J.R., van Zeventer I.A., Chitu D.A., Pabst T., Klein S.K., Stussi G., Griskevicius L., Valk PJM, Cloos J., van de Loosdrecht A.A., Breems D., van Lammeren-Venema D., Boersma R., Jongen-Lavrencic M., Fehr M., Hoogendoorn M., Manz M.G., Söhne M., van Marwijk Kooy R., Deeren D., van der Poel MWM, Legdeur M.C., Tick L., Chalandon Y., Ammatuna E., Blum S., Löwenberg B., Ossenkoppele G.J., Huls G.

Working group(s)

Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Swiss Group for Clinical Cancer Research (SAKK)

Contributor(s)

Chitu D.A., Klein S.K., Griskevicius L., Valk PJM, Cloos J., van de Loosdrecht A.A., Breems D., van Lammeren-Venema D., Boersma R., Jongen-Lavrencic M., Söhne M., van Marwijk Kooy R., Deeren D., van der Poel MWM, Legdeur M.C., Tick L., Ammatuna E., Löwenberg B., Ossenkoppele G.J., Huls G., Pabst T., Stussi G., Fehr M., Manz M.G., Chalandon Y., Blum S.

ISSN

2044-5385 (Electronic)

ISSN-L

2044-5385

Publication state

Published

Issued date

19/06/2023

Peer-reviewed

Oui

Volume

Number

Pages

Language

english

Notes

Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: epublish

Abstract

Treatment choice according to the individual conditions remains challenging, particularly in older patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). The impact of performance status, comorbidities, and physical functioning on survival is not well defined for patients treated with hypomethylating agents. Here we describe the impact of performance status (14% ECOG performance status 2), comorbidity (40% HCT-comorbidity index ≥ 2), and physical functioning (41% short physical performance battery < 9 and 17% ADL index < 6) on overall survival (OS) in 115 older patients (age ≥ 66 years) treated on a clinical trial with a 10-day decitabine schedule. None of the patient-related variables showed a significant association with OS. Multivariable analysis revealed that age > 76 years was significantly associated with reduced OS (HR 1.58; p = 0.043) and female sex was associated with superior OS (HR 0.62; p = 0.06). We further compared the genetic profiles of these subgroups. This revealed comparable mutational profiles in patients younger and older than 76 years, but, interestingly, revealed significantly more prevalent mutated ASXL1, STAG2, and U2AF1 in male compared to female patients. In this cohort of older patients treated with decitabine age and sex, but not comorbidities, physical functioning or cytogenetic risk were associated with overall survival.

Keywords

Humans, Male, Female, Aged, Decitabine/therapeutic use, Myelodysplastic Syndromes/genetics, Leukemia, Myeloid, Acute/genetics, Mutation, Treatment Outcome

URN

urn:nbn:ch:serval-BIB_4F3DD7E2D5288

OAI-PMH

oai:serval.unil.ch:BIB_4F3DD7E2D528

DOI

10.1038/s41408-023-00850-6

Pubmed

37336890

Web of science

001008860600001

Open Access

Yes